ONLINE SUPPLEMENT

Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate

Donald A. Mahler, MD¹ Jill A. Ohar, MD² Chris N. Barnes, PhD³ Edmund J. Moran, PhD³ Srikanth Pendyala, MD³ Glenn D. Crater, MD³

¹Geisel School of Medicine at Dartmouth, Hanover, New Hampshire and Respiratory Services, Valley Regional Hospital, Claremont, New Hampshire

²Wake Forest University Medical Center, Winston-Salem, North Carolina


³Theravance Biopharma US, Inc., South San Francisco, California

Methods

Randomization and Treatment Allocation

After screening, eligible patients were randomized to 1 of 2 treatment groups using Interactive Web Response System (Day 1/Visit 2) with the following stratification factors: baseline peak inspiratory flow rate (<40 L/min and \geq 40 L/min) against the resistance of Diskus; long-acting \Box -agonist use; and Global Initiative for Chronic Obstructive Lung Disease airway limitation grade (2, 3, and 4). Randomization was allocated centrally with blocking at the study site level.

e-Figure. Study Design



*PIFR measured using In-Check device at both resistances set to Diskus and Handihaler (for descriptive purposes)

AE = adverse event; IPR = ipratropium; MIP = maximal inspiratory pressure; PIFR = peak inspiratory flow rate